Julianna G Supplee1, Marina S D Milan2, Lee P Lim3, Kristy T Potts4, Lynette M Sholl5, Geoffrey R Oxnard6, Cloud P Paweletz7. 1. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, 360 Longwood Avenue, Boston, MA, 02215, USA. Electronic address: julianna_supplee@dfci.harvard.edu. 2. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Electronic address: MarinaS_Milan@dfci.harvard.edu. 3. Resolution Bioscience, Inc., 550 Kirkland Way, Kirkland, WA, 98033, USA. Electronic address: lplim@resolutionbio.com. 4. Resolution Bioscience, Inc., 550 Kirkland Way, Kirkland, WA, 98033, USA. Electronic address: kristy@resolutionbio.com. 5. Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. Electronic address: lmsholl@bwh.harvard.edu. 6. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Electronic address: geoffrey_oxnard@dfci.harvard.edu. 7. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, 360 Longwood Avenue, Boston, MA, 02215, USA. Electronic address: cloudp_paweletz@dfci.harvard.edu.
Abstract
OBJECTIVES: Plasma genotyping represents an opportunity for convenient detection of clinically actionable mutations in advanced cancer patients, such has been well-documented in non-small cell lung cancer (NSCLC). Oncogenic gene fusions are complex variants that may be more challenging to detect by next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA). Rigorous evaluation of plasma NGS assays in the detection of fusions is needed to maximize clinical utility. MATERIALS AND METHODS: Additional plasma was collected from patients with advanced NSCLC and ALK, ROS1, or RET gene fusions in tissue who had undergone clinical plasma NGS using Guardant360™(G360, Guardant Health). We then sequenced extracted cfDNA with a plasma NGS kit focused on known driver mutations in NSCLC (ctDx-Lung, Resolution Bioscience) with cloud-based bioinformatic analysis and blinded variant calling. RESULTS: Of 16 patients assayed known to harbor anALK, ROS1, or RET in tumor, G360 detected fusions in 7 cases, ctDx-Lung detected fusions in 13 cases, and 3 cases were detected by neither. Of the 7 fusions detected by both assays, G360 reported lower mutant allelic fractions (AF). In cases missed by G360, tumor derived TP53 mutations were often detected confirming presence of tumor DNA. Raw sequencing data showed that inverted or out-of-frame variants were overrepresented in cases detected using ctDx-Lung but not by G360. CONCLUSION: Focusing on complex, clinically actionable mutations using tumor as a reference standard allows for evaluation of technical differences in plasma NGS assays that may impact clinical performance. Noting the heterogeneity of fusion sequences observed in NSCLC, we hypothesize that differences in hybrid capture techniques and bioinformatic calling may be sources of variations in sensitivity among these assays.
OBJECTIVES: Plasma genotyping represents an opportunity for convenient detection of clinically actionable mutations in advanced cancerpatients, such has been well-documented in non-small cell lung cancer (NSCLC). Oncogenic gene fusions are complex variants that may be more challenging to detect by next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA). Rigorous evaluation of plasma NGS assays in the detection of fusions is needed to maximize clinical utility. MATERIALS AND METHODS: Additional plasma was collected from patients with advanced NSCLC and ALK, ROS1, or RET gene fusions in tissue who had undergone clinical plasma NGS using Guardant360™(G360, Guardant Health). We then sequenced extracted cfDNA with a plasma NGS kit focused on known driver mutations in NSCLC (ctDx-Lung, Resolution Bioscience) with cloud-based bioinformatic analysis and blinded variant calling. RESULTS: Of 16 patients assayed known to harbor anALK, ROS1, or RET in tumor, G360 detected fusions in 7 cases, ctDx-Lung detected fusions in 13 cases, and 3 cases were detected by neither. Of the 7 fusions detected by both assays, G360 reported lower mutant allelic fractions (AF). In cases missed by G360, tumor derived TP53 mutations were often detected confirming presence of tumor DNA. Raw sequencing data showed that inverted or out-of-frame variants were overrepresented in cases detected using ctDx-Lung but not by G360. CONCLUSION: Focusing on complex, clinically actionable mutations using tumor as a reference standard allows for evaluation of technical differences in plasma NGS assays that may impact clinical performance. Noting the heterogeneity of fusion sequences observed in NSCLC, we hypothesize that differences in hybrid capture techniques and bioinformatic calling may be sources of variations in sensitivity among these assays.
Authors: Charu Aggarwal; Christian D Rolfo; Geoffrey R Oxnard; Jhanelle E Gray; Lynette M Sholl; David R Gandara Journal: Nat Rev Clin Oncol Date: 2020-09-11 Impact factor: 66.675
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Stepan M Esagian; Georgia Ι Grigoriadou; Ilias P Nikas; Vasileios Boikou; Peter M Sadow; Jae-Kyung Won; Konstantinos P Economopoulos Journal: J Cancer Res Clin Oncol Date: 2020-05-27 Impact factor: 4.553
Authors: Adam J Schoenfeld; Joseph M Chan; Daisuke Kubota; Hiroki Sato; Hira Rizvi; Yahya Daneshbod; Jason C Chang; Paul K Paik; Michael Offin; Maria E Arcila; Monika A Davare; Ujwal Shinde; Dana Pe'er; Natasha Rekhtman; Mark G Kris; Romel Somwar; Gregory J Riely; Marc Ladanyi; Helena A Yu Journal: Clin Cancer Res Date: 2020-01-07 Impact factor: 12.531
Authors: Simon Heeke; Jonathan Benzaquen; Audrey Vallee; Maryline Allegra; Julien Mazieres; Julien Fayada; Jaya Rajamani; Michael Lee; Ellen Ordinario; Angelica Tiotiu; Jacques Cadranel; Michel Poudenx; Denis Moro-Sibilot; Fabrice Barlesi; Radj Gervais; Juliette Thariat; Virginie Tanga; Jacques Boutros; Marius Ilié; Véronique Hofman; Charles-Hugo Marquette; Marc G Denis; Paul Hofman Journal: Ann Transl Med Date: 2021-06
Authors: Catherine B Meador; Marina S D Milan; Emmy Y Hu; Mark M Awad; Michael S Rabin; Cloud P Paweletz; Ryan Hartmaier; Gianluca Laus; Geoffrey R Oxnard Journal: JCO Precis Oncol Date: 2021-06-01
Authors: Sebastian Mondaca; Emily S Lebow; Azadeh Namakydoust; Pedram Razavi; Jorge S Reis-Filho; Ronglai Shen; Michael Offin; Hai-Yan Tu; Yonina Murciano-Goroff; Chongrui Xu; Alex Makhnin; Andres Martinez; Nick Pavlakis; Stephen Clarke; Malinda Itchins; Adrian Lee; Andreas Rimner; Daniel Gomez; Gaetano Rocco; Jamie E Chaft; Gregory J Riely; Charles M Rudin; David R Jones; Mark Li; Tristan Shaffer; Seyed Ali Hosseini; Caterina Bertucci; Lee P Lim; Alexander Drilon; Michael F Berger; Ryma Benayed; Maria E Arcila; James M Isbell; Bob T Li Journal: Lung Cancer Date: 2021-07-17 Impact factor: 6.081